write a letter to the Editor regarding less availability of covid vaccines.
No spams.
Answers
Answer:
Eyebrows were raised at the nod given by the Drugs Controller General India to Bharat Biotech’s Covacin, albeit for use in clinical trial mode, in the absence of data on its efficacy from the phase-3 clinical trial. The D C G I did not show patience at the news briefing to elaborate on ‘clinical trial mode’. No amount of rationalisation can justify the hurry.
The proof of efficacy from peer-reviewed phase-3 trial data is an essential precondition for grant of approval for the vaccine. Conjecture cannot substitute evidence. The truth of the conjecture that a vaccine is efficacious has to be confirmed by hard data. The timing must be left to be decided by science.
Safety and efficacy of vaccines against SARS-Covid -2 are what matter; where vaccines are developed or manufactured is immaterial.
Vaccination should not become a subject for the hurly-burly of political debate. But the premature vaccine approval without the needed data cannot go unquestioned. By convincing people that the jab they get is safe and effective they can be persuaded out of vaccine hesitancy.
Name
address
Explanation:
please mark me as brainiest